Takeda Launches New Subsidiary in Peru
ZURICH, August 22, 2013
ZURICH, August 22, 2013 /PRNewswire/ --
Demonstrates Takeda's long-term commitment to the Latin American market
Takeda Pharmaceuticals International GmbH ("Takeda") today announced further
expansion of its presence in Latin America with the launch of a wholly-owned
subsidiary in Peru. Takeda Peru S.R.L. (Takeda Peru or "the Company") will be
headquartered in Lima and will be responsible for the sales and marketing of
Takeda's products in Peru.
Takeda is building a leading position in Latin America. It has a direct
presence in Brazil, Mexico, Argentina, Venezuela, Colombia, Ecuador and now
Peru, and is looking at opportunities to further expand its footprint in the
region. According to IMS Market Prognosis, pharmaceutical sales in those
countries totaled US$60 billion in 2012 and are expected to grow at a compound
annual rate of 12.5%* between 2013 and 2017. Takeda plans to outgrow the
market over the same period.
Peru is a dynamic and growing market, driven by government investment and
strong mining industries. It is estimated that the country's GDP totaled US$
200 billion in 2012 while pharmaceutical sales amounted to US$1.5 billion and
are expected to continue to grow by 8% during 2013*.
In line with Takeda's emerging markets strategy, Takeda Peru is building a
product portfolio based on the medical needs of the population, focusing on
gastroenterology, cardiology, metabolism, oncology and respiratory diseases.
The Company will initially focus on Zurcal ( pantoprazole ), Riopan (
Magaldrate + Dimeticone ) Faktu ( Policresulen, Cinchocaine hydrochloride) ,
and its gynaecology product, Albothyl ( Policresulen ), which Takeda
repatriated following the Nycomed acquisition.
Takeda plans to leverage its Peru sales platform with a steady stream of
product launches from its existing portfolio and R&D pipeline.
Julio Cesar Acevedo Orrego has been appointed country manager for Peru. He
joins the organization from Takeda Colombia, where he has built up and headed
the Takeda Sales and Marketing organization following the acquisition of
Farmacol Laboratories. He will lead the start-up team which will grow steadily
as the Company expands its portfolio and enters new therapeutic areas.
"The launch of our subsidiary in Peru reinforces Takeda's position in Latin
America and will enable us to meet the diverse healthcare needs of the
population. We have an established product portfolio, which will give us a
strong starting point and we look forward to launching our novel medicines
into the market," said Norbert Oppitz, Senior Vice President, Latin America,
at Takeda. "This investment further demonstrates our commitment to Latin
America and its growth potential."
^[ ^* ^] Data Source：© 2012 IMS Health. All rights reserved. Estimate based
on Market Prognosis Global 2012-2016.
About Takeda Pharmaceuticals International GmbH
Headquartered in Zurich as a wholly owned subsidiary of Takeda Pharmaceutical
Company Limited, Osaka, Japan, the company has a commercial presence covering
more than 70 countries, with particular strength in Asia, North America,
Europe and fast-growing emerging markets including Latin America, Russia-CIS
and China. Areas of focus include cardiovascular and metabolic, oncology,
respiratory and immunology, central nervous system, general medicine, and
Takeda is a research-based global company with its main focus on
pharmaceuticals. As the largest pharmaceutical company in Japan and one of the
global leaders of the industry, Takeda is committed to strive towards better
health for people worldwide through leading innovation in medicine. Through
the integration of Millennium Pharmaceuticals and Nycomed, Takeda has been
transforming itself, broadening its therapeutic expertise and geographic
Additional information about Takeda is available through its corporate
website, http://www.takeda.com .
This press release has been issued by Takeda Pharmaceuticals International
GmbH, Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland.
Contact: Contact: Takeda Pharmaceuticals International GmbH, Birgit
Gronkowski, +41-44-555-1506, Birgit.Grokowski@takeda.com
Press spacebar to pause and continue. Press esc to stop.